Perrigo shares are trading higher after the company announced it received FDA approval for Opill, an OTC daily oral contraceptive.
Portfolio Pulse from Benzinga Newsdesk
Perrigo Company plc (PRGO) announced that it has received FDA approval for Opill, an over-the-counter daily oral contraceptive. This news has led to an increase in the company's share price.
July 13, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Perrigo's stock price is trading higher following the FDA approval of its product, Opill. This approval could potentially increase the company's revenues and market share in the contraceptive industry.
The FDA approval of Perrigo's product, Opill, is a significant milestone for the company. This approval allows the company to sell the product over-the-counter, potentially increasing its revenues and market share. The news has already positively impacted the company's stock price, and it is likely to continue to do so in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100